Distinguished Professor of Pediatrics
University of California, San Diego
Dr. Bradley completed his Pediatric Infectious Diseases training at Stanford University in 1981, and has spent his time divided between clinical medicine and clinical research. He has focused his research on the development of antibacterial, antiviral and antifungal agents, with phase I, II and III clinical studies. His clinical research priority is the development of effective therapy for drug-resistant pathogens using pharmacokinetic/pharmacodynamic modeling for dose optimization. He works with industry, NICHD and FDA to promote safe and effective new therapy for neonates, infants and children. His current NICHD award supports PK/PD modeling work for beta-lactams in pediatric septic shock.
He holds the rank of Distinguished Professor in the Department of Pediatrics at the University of California San Diego, School of Medicine, and is the Medical Director of the Division of Infectious Diseases in the Rady Children's Hospital San Diego. He served as an active member of the FDA’s Anti-Infectives Advisory Drug Committee, and continues currently as an Advisor. He actively works with the academic community, FDA, industry and Congress to facilitate new, improved anti-infective agent development. His is also on the steering committee of USCAST, the United States Committee for Antimicrobial Susceptibility Testing, established to help regulatory agencies determine appropriate breakpoints for antibiotics, particularly important with emerging resistance to many agents. In addition, he serves on the organizing committee of the newly created I-ACT (Institute for Advanced Clinical Trials in Children), a public-private partnership to enhance successful clinical trials in children.
He was one of the pediatric members of the IDSA/CDC Influenza Guidelines Writing Committee (published March 2019), and is currently the cochair of the PIDS/IDSA Guidelines Writing Committee on Bone and Joint Infections in Children and the pediatric clinical member of the AHSP/IDSA Vancomycin Guidelines Writing Committee. . He is also the senior editor/writer of the American Academy of Pediatrics “Nelson’s Pediatric Antimicrobial Therapy” with John Nelson.